Company profile
Fulgent Genetics, Inc. logo

Fulgent Genetics, Inc.

Pipeline2 assets

  • FID-007FID-007 / Cytotoxic / Nanoencapsulated paclitaxel / Oncology
    Head and Neck (H&N) cancer, 2nd linePhase 2Ongoing; interim findings expected June 2026Ampullary or ICI resistant cancerGo/no-go based on H&N study
  • FID-022FID-022 / Cytotoxic / Oncology
    Colon cancerPhase 1Ongoing; dosing for 3rd dose level ongoingPancreatic cancerPhase 1Ongoing; dosing for 3rd dose level ongoingOvarian cancerPhase 1Ongoing; dosing for 3rd dose level ongoing

Latest news8 items

All news

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

EL MONTE, Calif. --(BUSINESS WIRE)--May 21, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on

Interim Data • Phase 2Rapid Oral Abstract Session Mon, Jun 1, 2026, 4:30 PM CDT

Fulgent Reports First Quarter 2026 Financial Results

Reiterates revenue guidance for fiscal year 2026 Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash Revenue of $71.1 million GAAP gross profit of $21.5 million, or GAAP gross margin of 30.2%; Non-GAAP gross

Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

EL MONTE, Calif. --(BUSINESS WIRE)--Apr. 16, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2026

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

EL MONTE, Calif. --(BUSINESS WIRE)--Mar. 17, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition of Bako Diagnostics, a

Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results

Revenue of $83.3 million, growing 9% year-over-year GAAP gross profit of $32.6 million, or GAAP gross margin of 39.1%; Non-GAAP gross profit of $34.2 million, or Non-GAAP gross margin of 41.0% GAAP loss of $23.4 million, or ( $0.76) per share; Non-GAAP income of $5.2 million, or $0.16 per share

Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base EL MONTE, Calif. --(BUSINESS WIRE)--Dec. 22, 2025-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and